MARICELLE GAMAD: Open Payments
NPI 1619344348 · MODESTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$783 in 33 payments from 13 companies in 2025. Trend: 2023 $770 · 2024 $704 · 2025 $783
Food & beverage: $783
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $177 |
| Janssen Pharmaceuticals, Inc | 4 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $80 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| Alkermes, Inc. | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Neurocrine BioSciences, Inc. | 2 | $47 |
| ACADIA Pharmaceuticals Inc | 2 | $45 |
| Merck Sharp & Dohme LLC | 2 | $42 |
| Lilly USA, LLC | 2 | $39 |
Products named: UZEDY, CAPLYTA, FANAPT, ARISTADA, INVEGA SUSTENNA, REXULTI, INGREZZA, NUPLAZID.
Industry payments across CA — which companies pay providers there.
